These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16498513)

  • 21. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Jang JS; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Kim DK; Seol SH; Kim DI; Cho KI; Kim BH; Park YH; Je HG; Jeong YH; Kim WJ; Lee JY; Lee SW
    Cardiology; 2012; 122(3):133-43. PubMed ID: 22832424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cilostazol Enhances Mobilization of Circulating Endothelial Progenitor Cells and Improves Endothelium-Dependent Function in Patients at High Risk of Cardiovascular Disease.
    Chao TH; Chen IC; Lee CH; Chen JY; Tsai WC; Li YH; Tseng SY; Tsai LM; Tseng WK
    Angiology; 2016 Aug; 67(7):638-46. PubMed ID: 27401788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.
    Zhang Z; Foster JK; Kolm P; Jurkovitz CT; Parker KM; Murrah NV; Anderson GT; Douglas JS; Weintraub WS
    Am Heart J; 2006 Oct; 152(4):770-6. PubMed ID: 16996857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
    Morishita R; Higaki J; Hayashi SI; Yo Y; Aoki M; Nakamura S; Moriguchi A; Matsushita H; Matsumoto K; Nakamura T; Ogihara T
    Diabetologia; 1997 Sep; 40(9):1053-61. PubMed ID: 9300242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cilostazol on intimal proliferation after directional coronary atherectomy.
    Tsuchikane E; Katoh O; Sumitsuji S; Fukuhara A; Funamoto M; Otsuji S; Tateyama H; Awata N; Kobayashi T
    Am Heart J; 1998 Mar; 135(3):495-502. PubMed ID: 9506336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
    Lee BK; Lee SW; Park SW; Lee SW; Park DW; Kim YH; Lee CW; Hong MK; Kim JJ; Jang S; Chi HS; Park SJ
    Am J Cardiol; 2007 Aug; 100(4):610-4. PubMed ID: 17697815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in the Mechanism and Clinical Application of Cilostazol.
    Zheng H; Yang H; Gong D; Mai L; Qiu X; Chen L; Su X; Wei R; Zeng Z
    Curr Top Med Chem; 2019; 19(31):2919-2936. PubMed ID: 31763974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial.
    Suh JW; Lee SP; Park K; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    Int Heart J; 2017 Dec; 58(6):853-860. PubMed ID: 29118299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cilostazol approved for use in intermittent claudication.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):404. PubMed ID: 10096695
    [No Abstract]   [Full Text] [Related]  

  • 33. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
    Stone WM; Demaerschalk BM; Fowl RJ; Money SR
    J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?
    Niazi AK; Dinicolantonio JJ; Lavie CJ; O'Keefe JH; Meier P; Bangalore S
    Cardiology; 2013; 126(4):233-43. PubMed ID: 24107485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol].
    Rosa MP; Baroni GV; Portal VL
    Arq Bras Endocrinol Metabol; 2007 Dec; 51(9):1528-32. PubMed ID: 18209897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
    Uchikawa T; Murakami T; Furukawa H
    Arzneimittelforschung; 1992 Mar; 42(3):322-4. PubMed ID: 1497693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts.
    Fujinaga K; Onoda K; Yamamoto K; Imanaka-Yoshida K; Takao M; Shimono T; Shimpo H; Yoshida T; Yada I
    J Thorac Cardiovasc Surg; 2004 Sep; 128(3):357-63. PubMed ID: 15354092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
    Lee TM; Su SF; Hwang JJ; Tseng CD; Chen MF; Lee YT; Wang SS
    Atherosclerosis; 2001 Oct; 158(2):471-6. PubMed ID: 11583728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.
    Hattori Y; Suzuki K; Tomizawa A; Hirama N; Okayasu T; Hattori S; Satoh H; Akimoto K; Kasai K
    Cardiovasc Res; 2009 Jan; 81(1):133-9. PubMed ID: 18703532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacology of cilostazol.
    Schrör K
    Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S14-9. PubMed ID: 12180353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.